Clinical Trial Update: Lactobacillus Rhamnosus GG (ATCC 53103) in Mild-moderately Active UC Patients [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial updating on Lactobacillus rhamnosus GG (ATCC 53103) in patients with mild-to-moderate ulcerative colitis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ulcerative Colitis

Drugs mentioned

• Lactobacillus rhamnosus GG (Lactobacillus rhamnosus GG)

Snippet

Sponsor: San Giovanni Addolorata Hospital | Conditions: Ulcerative Colitis Chronic Mild, Ulcerative Colitis Chronic Moderate | Phase 1, Phase 2 | Status: COMPLETED